Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 211   

Articles published

PFE 31.77 +0.07 (0.22%)
price chart
How Will Pfizer Inc. Fare Under President Trump?
President Trump could shake up the pharmaceutical world. If he delivers on his promises, it means that Pfizer (NYSE: PFE), one of the biggest of the big pharma companies, is in for some significant changes.
Should Pfizer, Inc. Be on Your Stock Watchlist?
Pfizer, Inc. (NYSE: PFE) is one of the largest drugmakers in the world, and management is making solid progress in kick-starting sales and profit growth following years of declining results tied to the loss of patent protection on Lipitor.
Pfizer CEO: This is what Trump doesn't understand about the pharma industry
Ian Read, chairman and chief executive officer of Pfizer Inc., gestures as he speaks during a panel session at the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 17, 2017.
Vetr Inc. Upgrades Pfizer, Inc. (PFE) to Strong-Buy
Pfizer logo Pfizer, Inc. (NYSE:PFE) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday.
Pfizer Inc. (PFE) Closes 0.22% Up on the Day for January 20  Equities.com
The Pfizer Inc. (PFE) Position Increased by Fragasso Group Inc.  DailyQuint
Large Inflow of Money Witnessed in Pfizer, Inc.
Pfizer, Inc. (NYSE:PFE) dropped by -1.03 or -0.33 points during the last session to $31.7 per share. One of the highlights of the day was the net money flow figure, which stood at $97.88 million even as the stock accepted $198.92 million in upticks but ...
The Stocks: Pfizer Inc. (PFE) Upgraded to Strong-Buy at Vetr Inc.  DailyQuint
Neuberger Berman Group LLC Has $813251000 Position in Pfizer Inc. (PFE)  Community Financial News
Pfizer Inc. (NYSE:PFE) Challenges Businessmen To Come Up With Breast Cancer ...
Pfizer Inc. (NYSE:PFE) is stepping up its battle against breast cancer. Perhaps in an effort to help Ibrance sales, a top breast cancer treatment, the biopharma giant says that patients suffering from this incurable cancer are more often than not ...
Crazy Volume Spikes for: Pfizer Inc. (NYSE:PFE)  FactsReporter
Pfizer, Inc. (PFE) Receives $37.28 Consensus PT from Analysts  Sports Perspectives
The Pfizer Inc. (PFE) Shares Sold by Jolley Asset Management LLC
Jolley Asset Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 0.1% during the third quarter, according to its most recent disclosure with the SEC.
Charter Trust Co Cuts Position in Pfizer (PFE)  Market Digest
Recent analysts Ratings: Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) will report its next earnings on 31-Jan-17. The company reported the earnings of $0.61/Share in the last quarter where the estimated EPS by analysts was $0.62/share.
Pfizer: 2 Risks Every Shareholder Should Be Aware Of
However, investors should be cautious as they invest in the company, since its risk factor could be a reasonable explanation for why the shares trade at current levels.
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint
Pfizer Inc. (NYSE:PFE) announced through the Business Wire on Jan. 5 that the results from a phase 3 study assessing the efficiency of PF-06410293, a biosimilar of AbbVie's (NYSE:ABBV) Humira, in treating patients affected by rheumatoid arthritis met ...